FDA approves Konect Resilia aortic valved conduit , the first ready-to-implant solution for bio-Bentall procedures, for aortic surgery. Edwards Life Sciences

Edwards Lifesciences Corporation announced it received approval from the FDA for the KONECT RESILIA aortic valved conduit (AVC), the first ready-to-implant solution for bio-Bentall procedures, a complex surgery that involves replacement of a patient’s aortic valve, aortic root and the ascending aorta.

“Until now, surgeons did not have a pre-assembled option that was FDA approved, so those utilizing bovine tissue valves for Bentall procedures needed to manually assemble a valve with a conduit in the operating room,” said Joseph E. Bavaria, MD, Brooke Roberts-William M. Measey professor of surgery and vice chief of the division of cardiovascular surgery, University of Pennsylvania. “The KONECT device represents a meaningful advancement that offers surgeons a pre-assembled device with two leading technologies, which can streamline treatment for patients requiring this complex and technical procedure.”